Prognostic impact and risk factors of cancer‐associated thrombosis events in stage‐IV cancer patients treated with immune checkpoint inhibitors

Abstract

The incidence of CAT in stage-IV cancer patients treated with ICIs was higher in our study compared to previous reports. Control group of patients who did not receive ICIs is needed for better identification of CAT risk factors. Khorana score was a good predictor of mortality but not CAT risk and needs to be further validated in a homogenous group of patients.